Long Shortz with Control Bionics: Major MedTech milestone with new US recognition

Stockhead’s Sarah Hughan sits down with Control Bionics’ (ASX:CBL) CEO and managing director Control Bionics to get the short end of the long story on the company’s latest news.

A new US insurance code has been approved for the company’s NeuroNode device which provides certain capabilities to individuals with conditions such as cerebral palsy.

Under the benefit, the technology has been recognised as a critical accessory for speech generating devices, saving thousands for patients.

Tune in to hear Control Bionics’ Jeremy Steele on the breakthrough’s significance, what else is cooking, and more.

This video was developed in collaboration with Control Bionics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.